Biogen Idec to Present at the Leerink Swann & Company/Medacorp Cancer Roundtable.CAMBRIDGE, Mass. -- Biogen Idec Biogen Idec, Inc. (NASDAQ: BIIB) is a biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen and San Diego, California-based Idec Inc. (NASDAQ/BIIB) announced today that its presentation at the Leerink Swann & Company/Medacorp Cancer Roundtable will be webcast live via the internet, on Monday, September 18, 2006 at 10:15 a.m. ET. To access the live webcast, please visit Biogen Idec's homepage, www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation. About Biogen Idec Biogen Idec creates new standards of care Standards of care are medical or psychological treatment guidelines, and can be general or specific. They specify appropriate treatment protocols based on scientific evidence, and collaboration between medical and/or psychological professionals involved in the treatment of a given in oncology, neurology neurology (n  rŏl`əjē, ny–), study of the morphology, physiology, and pathology of the human nervous system. and immunology immunology, branch of medicine that studies the response of organisms to foreign substances, e.g., viruses, bacteria, and bacterial toxins (see immunity). Immunologists study the tissues and organs of the immune system (bone marrow, spleen, tonsils, thymus, lymphatic . As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For product labeling, press releases and additional information about the company, please visit http://www.biogenidec.com.
|
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion